Effects of pralsetinib: A Synthesis of Findings from 19 Studies

  1. Home
  2. Effects of pralsetinib
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Effects of pralsetinib: A Synthesis of Findings from 19 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Effects of pralsetinib: A Synthesis of Findings from 19 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Major Findings

Pralsetinib is a targeted therapy that has shown promising results in treating patients with advanced or metastatic thyroid cancer and non-small cell lung cancer with RET gene alterations. 10 、 19 、 13 、 18 、 14 These studies indicate that pralsetinib can effectively shrink tumors and slow down the progression of the disease, particularly when used as a first-line treatment. 19 It is noteworthy that pralsetinib can also potentially cause chylous ascites, a build-up of fluid in the abdomen, in patients with RET-altered lung cancer.

Benefits and Risks

Benefit Summary

Pralsetinib offers a potential treatment option for patients with advanced or metastatic thyroid cancer and non-small cell lung cancer with RET gene alterations, providing hope for shrinking tumors and slowing disease progression. 10 、 19 、 13 、 18 、 14 Its use as a first-line treatment may yield particularly positive outcomes. 19

Risk Summary

Pralsetinib, like other medications, can cause side effects. Some common side effects include high blood pressure, elevated liver enzymes, QT prolongation, neutropenia, and pneumonia. 11 Additionally, pralsetinib has been associated with the potential for chylous ascites, a buildup of fluid in the abdomen, in patients with RET-altered lung cancer.

Comparison across Studies

Commonalities

Many studies consistently highlight the potential effectiveness of pralsetinib in treating advanced or metastatic thyroid cancer and non-small cell lung cancer with RET gene alterations. 10 、 19 、 13 、 18 、 14 These research findings consistently indicate that pralsetinib shows promise in shrinking tumors and slowing the progression of these diseases.

Differences

Differences exist in the observed effects and side effects of pralsetinib across various studies. For instance, while high blood pressure, elevated liver enzymes, QT prolongation, neutropenia, and pneumonia have been reported as potential side effects, their frequency and severity vary between studies. 11 Similarly, the incidence and severity of chylous ascites, a build-up of fluid in the abdomen, in patients with RET-altered lung cancer, have also shown variation across studies.

Consistency and Inconsistencies in Findings

A consistent theme across various studies is the potential effectiveness of pralsetinib in treating advanced or metastatic thyroid cancer and non-small cell lung cancer with RET gene alterations. 10 、 19 、 13 、 18 、 14 These studies demonstrate pralsetinib's ability to shrink tumors and slow the progression of these diseases. However, discrepancies exist in the reported frequency and severity of side effects, requiring further investigation. 11 、 More research is needed to gather more detailed information about pralsetinib's side effects.

Practical Implications and Cautions

Pralsetinib holds potential as a treatment option for advanced or metastatic thyroid cancer and non-small cell lung cancer with RET gene alterations. 10 、 19 、 13 、 18 、 14 However, the possibility of side effects necessitates careful adherence to medical guidance during treatment. 11 Consulting a doctor to discuss treatment options and make informed decisions about the best course of action is crucial for patients considering pralsetinib.

Limitations of Current Research

Research on pralsetinib is ongoing, and further investigation is necessary. Long-term effects and safety data regarding pralsetinib remain insufficient. It is also unclear whether pralsetinib is effective for all patients with RET gene alterations or if its benefits are specific to certain types of alterations. Additionally, inconsistencies in the reported frequency and severity of side effects necessitate further research to collect more comprehensive information. 11 、

Future Research Directions

Further research is crucial to gain a deeper understanding of pralsetinib's long-term effects and safety, as well as to identify the specific types of RET gene alterations where pralsetinib is most effective. Additional studies are also needed to clarify the frequency and severity of pralsetinib's side effects. These research efforts will contribute to a more comprehensive understanding of pralsetinib's potential benefits and risks.

Conclusion

Pralsetinib holds promise as a potential treatment option for advanced or metastatic thyroid cancer and non-small cell lung cancer with RET gene alterations. 10 、 19 、 13 、 18 、 14 However, it is important to be aware of its potential side effects and to work closely with a healthcare provider to manage treatment effectively. 11 Consulting with a doctor to discuss personalized treatment options is essential for informed decision-making. Further research is necessary to fully understand the long-term effects and safety of pralsetinib. 11

Literature analysis of 19 papers
Positive Content
17
Neutral Content
2
Negative Content
0
Article Type
8
1
2
5
19
1.

[Comparison of PVRV and HDCV rabies vaccines as to immunity, reliability and protective value].

Author: HacibektaşoğluA, InalA, EyigünC, BarutA, TürkayF A

Rabies prophylaxis
Fever
Local pain
Lymphadenopathy

PVRV and HDCV vaccines for rabies were equally effective in inducing neutralizing antibodies in healthy male volunteers. Both vaccines provided a year-long protection until the first booster dose.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
English AbstractA summary of a research paper/publication written in English for a wider audience.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : Turkish

2.

Immunoenhancement with combined rabies and aluminium-adjuvanted tetanus vaccines.

Author: PhanuphakP, KhaoplodP, SriwanthanaB, PhanpanichT, WonguraiS, RoumiantzeffM

immunoenhancement
vaccine efficacy increase

Combining tetanus toxoid with purified Vero cell rabies vaccine (PVRV) in the 2-1-1 regimen significantly increased anti-rabies antibody levels, but only when aluminum hydroxide-adsorbed tetanus toxoid was used. This combination did not affect anti-tetanus antibody levels or increase side effects.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

3.

Anti-rabies treatment of dog-bite victims in Lagos, Nigeria: trial of suckling mouse brain and fetal bovine kidney cell rabies vaccines.

Author: HarryT O, AdeigaA, AnyiwoC E, NasidiA

Prevents rabies
Generalized reactions
Local reactions

Suckling mouse brain (SMBV) and fetal bovine kidney (FBKV) rabies vaccines were equally efficacious and well tolerated in dog-bite victims.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

4.

Immunogenicity and safety in adults of a new chromatographically purified Vero-cell rabies vaccine (CPRV): a randomized, double-blind trial with purified Vero-cell rabies vaccine (PVRV).

Author: LangJ, CetreJ C, PicotN, LantaM, BriantaisP, VitalS, Le MenerV, LutschC, RotivelY

Rabies vaccination
Asthenia

A new chromatographically purified rabies vaccine (CPRV) was found to be as immunogenic as purified Vero cell vaccine (PVRV) and associated with fewer systemic reactions in a randomized, double-blind study.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

5.

Immunogenicity and efficacy of Fermi-type nerve tissue rabies vaccine in mice and in humans undergoing post-exposure prophylaxis for rabies in Ethiopia.

Author: AyeleW, FekaduM, ZewdieB, BeyeneM, BogaleY, MochaK, EgziabherF G

Rabies prophylaxis

This study assessed the immunogenicity and efficacy of a Fermi-type rabies vaccine in mice and humans. In mice, the vaccine induced protective levels of rabies virus neutralizing antibodies (VNA). Booster doses did not significantly enhance the immune response. In humans, most patients receiving the vaccine had detectable VNA levels by day 14. The study provides the first documentation of the efficacy and immunogenicity of this specific rabies vaccine in both humans and mice.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

6.

Sex-differential non-specific effects of rabies vaccine in dogs: An extended analysis of a randomized controlled trial in a high-mortality population.

Author: KnobelDarryn L, AregaSintayehu M, ConanAnne

All-cause mortality

This study found a significant sex-specific effect of non-live rabies vaccination on all-cause mortality in a high-mortality dog population. Primary vaccination increased the hazard of death among females, while a second dose decreased the hazard among males. These findings highlight the importance of considering sex-specific effects when evaluating vaccine efficacy.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

7.

Non-specific effects of maternal and offspring rabies vaccination on mortality and antibiotic use in a Danish pig herd: A randomized trial.

Author: JensenKristoffer Jarlov, TolstrupLola Kathe, KnobelDarryn L, AabyPeter, JungersenGregers, LarsenLars Erik, KristensenCharlotte Sonne, BennChristine Stabell

Rabies vaccination
Non-specific effects

This study investigated the non-specific effects (NSE) of rabies vaccine in piglets, particularly the potential modifying effect of maternal priming with the vaccine.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

8.

Non-specific effects of rabies vaccine on the incidence of self-reported common infectious disease episodes: A randomized controlled trial.

Author: OditaChristianah I, ConanAnne, Smith-AntonyMarshalette, BatticeJuliet, EnglandShianne, BarryDonna, GessnerBradford D, KnobelDarryn L

This randomized controlled trial investigated whether a rabies vaccine could protect against other common infections. The results showed no significant difference in the incidence of common infections between vaccinated and unvaccinated participants. This suggests that the rabies vaccine does not offer broad protection against other infections.

Clinical Trial, Phase IVPost-marketing surveillance. Monitors long-term safety/efficacy after approval.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

9.

Immunogenicity and safety of human diploid cell vaccine (HDCV) vs. purified Vero cell vaccine (PVRV) vs. purified chick embryo cell vaccine (PCECV) used in post-exposure prophylaxis: a systematic review and meta-analysis.

Author: WangShi-Yuan, SunJin-Fang, LiuPei, LuoLi, LiJing-Xin, ZhuFeng-Cai, ShenXu-Xiang, MengFan-Yue

Rabies prevention
Adverse reactions

Human diploid cell vaccine (HDCV) was found to be safer than purified vero cell vaccine and PCECV in terms of adverse reactions. However, no significant difference was observed in terms of immunogenicity.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

10.

Pralsetinib in Patients with Advanced/metastatic RET-altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study.

Author: SubbiahVivek, HuMimi I, MansfieldAaron S, TaylorMatthew H, SchulerMartin, ZhuViola W, HadouxJulien, CuriglianoGiuseppe, WirthLori, GainorJustin F, AlonsoGuzman, AdkinsDouglas R, GodbertYann, AhnMyung-Ju, CassierPhilippe A, Chul ChoByoung, LinChia-Chi, ZalutskayaAlena, BarataTeresa, TraskPeter, ScaloriAstrid, BordognaWalter, HeinzmannSebastian, BroseMarcia

Thyroid cancer treatment

This study presents an updated analysis of the ARROW study, which evaluated the efficacy and safety of pralsetinib, a selective RET inhibitor, in patients with advanced/metastatic RET-altered thyroid cancer. The analysis confirms the clinical activity and manageable safety profile of pralsetinib in this patient population.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

11.

Efficacy and Safety of RET-Specific Kinase Inhibitors in RET-Altered Cancers: A Systematic Review.

Author: AliMuhammad Ashar, ShahSyed S, AliRimsha, BajwaShammas Farooq, RehmanSana, AnwarAqsa, AnwarMuhammad Yasir, SaeedMemoona, MirzaNayab, AimanWajeeha

RET-altered tumor treatment
ALT changes
Hypertension
Neutropenia
Pneumonitis
QT prolongation

Selpercatinib and pralsetinib are the only FDA-approved RET-specific tyrosine kinase inhibitors for RET-altered tumors. This review summarizes the efficacy and safety of these drugs based on a comprehensive literature search. Objective response rates were 60-89%, and ≥Grade 3 adverse events were reported in 28-53% of patients.

Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

12.

Precision oncology with selective RET inhibitor selpercatinib in <i>RET</i>-rearranged cancers.

Author: GoudaMohamed A, SubbiahVivek

Targeted therapy
Treatment of RET fusion-positive tumors
None reported

This article reviews the current status of selpercatinib, a selective RET inhibitor, for treating RET fusion-positive tumors. Selpercatinib has demonstrated efficacy in treating non-small cell lung cancer (NSCLC), thyroid cancers, and other RET-positive tumors.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

13.

Efficacy and safety of pralsetinib in patients with advanced RET fusion-positive non-small cell lung cancer.

Author: ZhouQing, ZhaoJun, ChangJianhua, WangHuijie, FanYun, WangKe, WuGang, NianWeiqi, SunYuping, SunMeili, WangXiangcai, ShiHuaqiu, ZhengXiangqian, YaoSheng, QinMengmeng, ShenZhenwei, YangJason, WuYi-Long

Pralsetinib efficacy
Pralsetinib safety

Pralsetinib, a RET inhibitor, demonstrated robust and durable clinical activity with a well-tolerated safety profile in Chinese patients with RET fusion-positive non-small cell lung cancer (NSCLC). The objective response rate was 66.7% in pretreated patients and 83.3% in treatment-naive patients. Median progression-free survival was 11.7 months in pretreated patients and 12.7 months in treatment-naive patients. The most common grade 3/4 treatment-related adverse events were anemia (35.3%) and decreased neutrophil count (33.8%).

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

14.

Expanded Access Program Pralsetinib in Advanced Non-Small Cell Lung Cancer with Rearranged during Transfection (RET) Gene Rearrangement.

Author: JeonYoungkyung, JungHyun Ae, ParkSehhoon, SunJong-Mu, AhnJin Seok, AhnMyung-Ju, ParkKeunchil, LeeSe-Hoon

NSCLC treatment

Pralsetinib is a selective RET kinase inhibitor that has shown efficacy in RET-altered tumors. This study evaluated the efficacy and safety of pralsetinib in pretreated, advanced NSCLC patients with RET rearrangement.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

17.

Precious Gene: The Application of RET-Altered Inhibitors.

Author: GouQitao, GanXiaochuan, LiLonghao, GouQiheng, ZhangTao

RET-altered cancer treatment

Novel RET-specific inhibitors, selpercatinib and pralsetinib, have been approved by the FDA for the treatment of RET-altered cancers, offering a significant advancement over multikinase inhibitors (MKIs). These new inhibitors demonstrate high potency and selectivity, with improved tolerability and efficacy. Clinical trials of other RET inhibitors, such as TPX-0046 and zetletinib, are ongoing.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

18.

Pralsetinib in RET fusion-positive non-small-cell lung cancer: A real-world data (RWD) analysis from the Italian expanded access program (EAP).

Author: PassaroAntonio, RussoGiuseppe Lo, PassigliaFrancesco, D'ArcangeloManolo, SbranaAndrea, RussanoMarco, BonannoLaura, GiustiRaffaele, MetroGiulio, BertoliniFederica, GrisantiSalvatore, CartaAnnamaria, CecereFabiana, MontroneMichele, MassaGiacomo, PerroneFabiana, SimionatoFrancesca, GuaitoliGiorgia, ScottiVieri, GenovaCarlo, LuginiAntonio, BonomiLucia, AttiliIlaria, de MarinisFilippo

Durable activity
Intracranial response
Treatment related adverse events

Pralsetinib demonstrated durable systemic activity and intracranial response in RET-fusion positive non-small cell lung cancer (NSCLC) in a real-world setting. The objective response rate (ORR) was 66% and the disease control rate (DCR) was 79%. The toxicity profile was consistent with previous reports.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

19.

Safety and efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial.

Author: GriesingerF, CuriglianoG, ThomasM, SubbiahV, BaikC S, TanD S W, LeeD H, MischD, GarraldaE, KimD-W, van der WekkenA J, GainorJ F, Paz-AresL, LiuS V, KalemkerianG P, HouvrasY, BowlesD W, MansfieldA S, LinJ J, SmoljanovicV, RahmanA, KongS, ZalutskayaA, Louie-GaoM, BoralA L, MazièresJ

Antitumor activity

Pralsetinib, a selective RET inhibitor, showed clinical activity in patients with RET fusion-positive non-small-cell lung cancer (NSCLC), including treatment-naive patients, as demonstrated in the ARROW study. This updated analysis provides further insights into the effectiveness of pralsetinib.

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.